Welcome to our dedicated page for PJT Partners news (Ticker: $PJT), a resource for investors and traders seeking the latest updates and insights on PJT Partners stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PJT Partners's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PJT Partners's position in the market.
PJT Partners Inc. reported record first-quarter results for 2024, including a 65% revenue increase to $329 million, GAAP pretax income of $54 million, and adjusted pretax income of $55 million. The company also achieved an 82% increase in GAAP diluted EPS to $1.22 and an 81% increase in adjusted EPS to $0.98 from a year ago. Additionally, PJT repurchased 1.5 million share equivalents, held $236 million in cash, cash equivalents, and short-term investments with no funded debt, and declared a $0.25 per share dividend. The company plans to repurchase more shares and remains confident in its future growth prospects.
